CARAC
LOE Approachingfluorouracil cream, 0.5%
NDATOPICALCREAM
Approved
Oct 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
CARAC (fluorouracil cream, 0.5%) is nucleic acid synthesis inhibitors [moa]. First approved in 2000.
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARAC is a topical fluorouracil cream (0.5%) approved in 2000 for treatment of actinic keratosis and other skin conditions. It functions as a nucleic acid synthesis inhibitor, disrupting rapidly dividing cells in precancerous and cancerous skin lesions. The drug is administered as a cream applied directly to affected skin areas.
$0.049BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Part D spending ($49K) and only 20 claims in 2023, signaling a mature, low-volume commercial footprint with limited team investment opportunities.
Mechanism of Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Class:
Nucleoside Metabolic Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Carac & PDT Combination in the Treatment Of Actinic Keratoses
Started Aug 2008
60 enrolled
Actinic Keratoses
Career Relevance
CARAC presents limited career growth opportunities due to its LOE-approaching status and minimal commercial spending. Career value lies primarily in managing a mature brand through transition phases, gaining experience in generic competition strategy, or supporting regulatory compliance related to off-label safety signals.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.